Bicycle Therapeutics Plc
(NASDAQ : BCYC)

( )
BCYC After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc. 4.03%69.701.0%$1071.78m
BIIBBiogen, Inc. 0.02%336.711.5%$665.47m
AMGNAmgen, Inc. 0.29%222.791.3%$550.81m
ILMNIllumina, Inc. -1.50%295.943.5%$414.21m
VRTXVertex Pharmaceuticals, Inc. 0.49%246.291.9%$346.37m
REGNRegeneron Pharmaceuticals, Inc. 1.01%403.152.6%$345.56m
ALXNAlexion Pharmaceuticals, Inc. 0.59%103.142.0%$220.13m
AAgilent Technologies, Inc. 0.85%85.061.6%$165.05m
EXASEXACT Sciences Corp. -2.59%99.9824.0%$144.57m
INCYIncyte Corp. -2.27%80.892.5%$113.92m
SGENSeattle Genetics, Inc. -1.12%117.006.1%$113.16m
BMRNBioMarin Pharmaceutical, Inc. 6.13%95.164.3%$102.95m
MRNAModerna, Inc. -1.67%18.230.0%$98.70m
XLRNAcceleron Pharma, Inc. -0.36%94.516.1%$91.83m
ALNYAlnylam Pharmaceuticals, Inc. -1.57%131.038.7%$91.49m

Company Profile

Bicycle Therapeutics Plc is a holding company, which engages in the development of biopharmaceuticals. It focuses on developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.